Primary bone cancer

Last updated: 07 May 2026
Reviewed by: Specialist doctors from the Elfcare quality team

Feeling persistent aches in your joints or bones, or noticing fatigue and stiffness that doesn’t seem to go away? While these changes are often linked to activity or age, persistent localized bone pain, especially pain that worsens at night or doesn't improve with rest, should be investigated to understand what is happening beneath the surface.

Primary bone cancer is rare, accounting for less than 1% of all cancers, but its rarity makes it easy to dismiss early symptoms as muscle strain or growing pains. It most commonly affects children, adolescents, and young adults, and outcomes are significantly better when structural changes are identified early through imaging.

Book your consultation to test your health

What is primary bone cancer?

Primary bone cancer originates in the bone tissue itself (in the bone cells, cartilage cells, or supporting connective tissue) rather than spreading from another site. The three main types are:

  • Osteosarcoma: the most common primary bone cancer; arises from bone-forming cells, most often in the long bones of the limbs (femur, tibia, humerus) near the growth plates. Predominantly affects adolescents and young adults.

  • Chondrosarcoma: arises from cartilage-producing cells; more common in adults over 40; most frequently affects the pelvis, femur, and shoulder

  • Ewing sarcoma: arises from primitive cells in bone or surrounding soft tissue; affects the pelvis, femur, ribs, and spine; predominantly affects children and young adults

Unlike bone metastases, primary bone cancers are not preceded by cancer elsewhere, they arise de novo from malignant transformation of local bone or cartilage cells.

Symptoms of primary bone cancer

Primary bone cancer symptoms develop gradually and are frequently attributed to sports injuries or growing pains, particularly in adolescents. Common signs include:

  • Persistent bone pain — often worse at night and not relieved by rest; a key distinguishing feature from musculoskeletal pain

  • Localised swelling, warmth, or tenderness over a bone

  • A palpable hard mass over the affected area

  • Pathological fracture — a fracture with minimal or no trauma, caused by structurally weakened bone

  • Reduced range of motion near the affected joint

  • Unexplained fatigue and weight loss in more advanced disease

What causes primary bone cancer?

In most cases no specific cause is identified. Known risk factors include:

  • Genetic syndromes: Li-Fraumeni syndrome (TP53), hereditary retinoblastoma, neurofibromatosis type 1, and Rothmund-Thomson syndrome all carry elevated osteosarcoma risk

  • Prior radiation therapy: high-dose radiation is the most clearly established environmental cause; radiation-induced sarcomas typically arise 5–20 years after treatment

  • Paget's disease of bone: a chronic bone remodelling disorder that can rarely transform into osteosarcoma in older adults

  • Rapid bone growth: the association of osteosarcoma with adolescent growth spurts suggests a link between rapid cellular proliferation and malignant transformation

How is primary bone cancer detected?

Primary bone cancer is detected primarily through imaging, with blood tests providing supporting metabolic context. A definitive diagnosis always requires biopsy.

MRI is the primary tool for assessing bone cancer, defining tumor size, location, and involvement of nearby nerves or soft tissue. Elfcare’s full body MRI images the spine, pelvis, and long bones, the most common sites for these lesions. While MRI characterizes the abnormality and guides biopsy planning, targeted regional scans are available for high-resolution limb assessment.

Blood tests cannot detect primary bone cancer directly but provide relevant supporting information. Relevant markers in Elfcare's panel include:

  • ALP (alkaline phosphatase): elevated in osteosarcoma, reflecting abnormal bone formation activity

  • Calcium and phosphate: bone mineral markers; relevant to metabolic bone health

  • CRP: systemic inflammation; elevated in advanced disease

  • LDH (lactate dehydrogenase):not in Elfcare's standard panel; elevated LDH is a prognostic marker in Ewing sarcoma, arranged through specialist workup

  • Vitamin D: supports bone mineralisation; deficiency complicates bone health assessment

Why early detection matters

Primary bone cancer outcomes are strongly stage-dependent. Localised osteosarcoma treated with surgery and chemotherapy has a five-year survival rate of approximately 60–70%. Metastatic disease at diagnosis significantly worsens outcomes. Early identification of suspicious bone lesions, before local invasion or metastatic spread, expands treatment options and improves prognosis significantly.

How Elfcare can help

Elfcare's full body MRI covers the spine, pelvis, and proximal limb structures — and can identify suspicious bone lesions as incidental findings. Targeted regional MRI is available for specific peripheral sites. Our blood panel provides supporting metabolic context.

A definitive diagnosis requires biopsy, but if a suspicious finding is made, we take care of further diagnostics or refer you to the appropriate specialist, ideally a sarcoma centre with specialist multidisciplinary expertise.

Book a consultation to learn more
Book a consultation to learn more

Summary

Primary bone cancer is rare but serious, with outcomes strongly dependent on the stage at detection. Elfcare's full body MRI can identify suspicious bone lesions in the spine, pelvis, and proximal limbs, with targeted regional MRI available for peripheral sites. Blood tests provide supporting metabolic context. A definitive diagnosis requires biopsy, but if a suspicious finding is made, we take care of further diagnostics or refer you to the appropriate specialist. Proactive screening ensures that potential issues are addressed early, protecting your long term mobility and bone health throughout your life.

Last updated: 07 May 2026
Reviewed by: Specialist doctors from the quality team at Elfcare

FAQ

  • Primary bone cancer originates in the bone itself, in bone cells (osteosarcoma), cartilage cells (chondrosarcoma), or primitive connective tissue (Ewing sarcoma). It is distinct from bone metastases, where cancer from another organ spreads to bone. It is rare, accounting for less than 1% of all cancers.

  • Persistent bone pain (worse at night), localised swelling or a hard mass over a bone, pathological fractures, reduced joint mobility, and fatigue. Symptoms are frequently attributed to sports injuries or growing pains, particularly in adolescents, causing diagnostic delay.

  • In most cases no specific cause is identified. Known risk factors include genetic syndromes (Li-Fraumeni, retinoblastoma), prior radiation therapy, Paget's disease, and rapid bone growth in adolescence.

  • MRI is the primary imaging tool, defining tumour extent and guiding biopsy. Blood tests provide supporting metabolic information. A definitive diagnosis always requires tissue biopsy to confirm malignancy and determine subtype.

  • Elfcare's full body MRI can identify suspicious bone lesions in the spine, pelvis, and proximal limbs, with targeted regional MRI available for peripheral sites. A definitive diagnosis requires biopsy. If a suspicious finding is made, we take care of further diagnostics or refer you to the appropriate specialist.

  • Yes. Treatment depends on type, grade, size, and stage. Osteosarcoma is treated with surgery and chemotherapy. Ewing sarcoma with chemotherapy, surgery, and radiotherapy. Chondrosarcoma primarily with surgery. Treatment is best delivered at a designated sarcoma centre. Early detection significantly expands treatment options and improves outcomes.